bomedemstat for high-risk myelofibrosis
Published 3 years ago • 269 plays • Length 2:51Download video MP4
Download video MP3
Similar videos
-
7:10
bomedemstat in jak inhibitor-resistant myelofibrosis
-
5:40
results of phase ii study of bomedemstat in myelofibrosis
-
7:42
phase ii trial of bomedemstat for advanced myelofibrosis
-
3:35
analysis from most: disease progression and leukemic transformation in lower-risk myelofibrosis
-
2:44
myelofibrosis: jenson shares his experience
-
3:33
transformation of essential thrombocythemia
-
3:29
unmet needs and therapeutic strategies in essential thrombocythemia
-
1:49
mechanism of action of bomedemstat
-
1:19
telomerase inhibition as a novel targeted therapy for myelofibrosis
-
2:00
the role of fedratinib in 2024 and beyond
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
1:43
updates from a phase ii study of bomedemstat for the treatment of essential thrombocythemia
-
1:15
exploring the evolving treatment landscape of myelofibrosis
-
1:41
novel therapies for high-risk mds
-
1:24
imetelstat in high-risk triple-negative myelofibrosis
-
4:26
bet inhibition as a novel targeted therapy for myelofibrosis
-
1:03
most: an observational study of myelofibrosis and essential thrombocythemia
-
4:39
imetelstat shows promise in advanced myelofibrosis
-
1:28
comorbidities and treatment decisions in myelofibrosis
-
2:41
bomedemstat combined with ruxolitinib for the treatment of mf: early results of a phase ii trial
-
3:19
finding novel targets for myelofibrosis from animal models